唐氏综合征相关急性淋巴细胞白血病移植结局:治疗强度与新型疗法的启示
日本全国性回顾性分析2000至2022年接受首次异基因造血干细胞移植的<30岁B细胞前体ALL患者,其中DS-ALL 56例、非DS-ALL 3873例。DS-ALL的4年EFS低于非DS-ALL(40.3% vs 55.2%),但按移植时疾病状态分层后相似;复发而非NRM是DS-ALL治疗失败的主要原因。在CR1/2期DS-ALL患者中,MAC较RIC有更优EFS趋势,RIC与更高NRM相关。
要点
- DS-ALL移植后4年EFS低于非DS-ALL,但按移植时疾病状态分层后相似。
- 复发而非NRM是DS-ALL移植后治疗失败的主要原因。
- CR1/2期DS-ALL患者中MAC较RIC有更优EFS趋势,RIC与更高NRM相关。
核心结论
- DS-ALL患者移植后4年EFS低于非DS-ALL,但按移植时疾病状态分层后相似。
- 复发而非NRM是DS-ALL移植后治疗失败的主要原因。
- CR1/2期DS-ALL患者中MAC较RIC有更优EFS趋势,RIC与更高NRM相关。
- 不能耐受MAC的CR1/2期DS-ALL患者可考虑新型疗法而非RIC-HSCT。
研究设计与样本
- 日本全国性回顾性分析2000至2022年接受首次异基因HSCT的<30岁B细胞前体ALL患者。
- 共纳入DS-ALL 56例和非DS-ALL 3873例。
主要发现
- 中性粒细胞植入、II-IV级急性GVHD和慢性GVHD发生率两组相当。
- DS-ALL的4年EFS低于非DS-ALL(40.3% vs 55.2%),但按移植时疾病状态分层后相似。
- DS-ALL首次和第二次完全缓解(CR1/CR2)的4年EFS分别为62.7%和48.2%,非DS-ALL分别为69.5%和56.0%。
- 复发而非NRM是DS-ALL治疗失败的主要原因。
- CR1/2期DS-ALL患者中MAC较RIC有更优EFS趋势,RIC与更高NRM相关。
关键数值与推荐
- DS-ALL 4年EFS 40.3%,非DS-ALL 55.2%。
- DS-ALL CR1和CR2的4年EFS分别为62.7%和48.2%,非DS-ALL分别为69.5%和56.0%。
- CR1/2期DS-ALL患者中MAC较RIC有更优EFS趋势,RIC与更高NRM相关。
临床怎么用
- DS-ALL移植后应重视复发监测,复发是主要失败原因。
- CR1/2期DS-ALL患者若可耐受MAC,MAC可能较RIC有更优EFS趋势。
- 不能耐受MAC的CR1/2期DS-ALL患者可考虑新型疗法而非RIC-HSCT。
局限性
- 回顾性研究设计。
- DS-ALL样本量有限(56例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Down syndrome-associated acute lymphoblastic leukaemia (DS-ALL) is associated with inferior outcomes compared with non-DS-ALL; however, data on haematopoietic stem cell transplantation (HSCT) in DS-ALL remain limited. We analysed nationwide data of patients aged <30 years with B-cell precursor ALL who underwent first allogeneic HSCT between 2000 and 2022 in Japan. In total, 56 patients with DS-ALL and 3873 with non-DS-ALL were identified. The incidences of neutrophil engraftment, grade II-IV acute graft-versus-host disease and chronic graft-versus-host disease were comparable between groups. The 4-year event-free survival (EFS) was lower in DS-ALL than in non-DS-ALL (40.3% vs. 55.2%), but was similar when stratified by disease status at HSCT. The 4-year EFS rates in first and second complete remission (CR) were 62.7% and 48.2% in DS-ALL and 69.5% and 56.0% in non-DS-ALL respectively. Relapse, rather than non-relapse mortality (NRM), was the leading cause of treatment failure in DS-ALL. Among patients with DS-ALL undergoing HSCT in CR1/2, myeloablative conditioning (MAC) showed a trend towards superior EFS compared with reduced-intensity conditioning (RIC), which was associated with a higher incidence of NRM. Accordingly, patients in CR1/2 who are unable to tolerate MAC are considered good candidates for emerging novel therapies rather than RIC-HSCT.
引用
- Ishida H, Okamoto Y, Sakaguchi H, et al. Transplantation outcomes in patients with Down syndrome-associated acute lymphoblastic leukaemia: Implications for treatment intensity and the use of novel therapies. Br J Haematol. 2026. PMID: 42178886. doi:10.1111/bjh.70583
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。